LIVIVO - Search results -

Search results

Result 1 - 10 of total 37

Search options

Article ; Online: Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis.

Ng, Wern Hann / Tipih, Thomas / Makoah, Nigel A / Vermeulen, Jan-G / Goedhals, Dominique / Sempa, Joseph B / Burt, Felicity J / Taylor, Adam / Mahalingam, Suresh

mBio

2021 Volume 12, Issue 1

Abstract: ... to be the most prevalent comorbidities in COVID-19 patients. Our meta-analysis showed that cancer ... in the exacerbation of disease in COVID-19 patients leading to fatal outcomes. A systematic review was conducted using ... Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across the globe ...

Abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread across the globe at unprecedented speed and is showing no signs of slowing down. The outbreak of coronavirus disease 2019 (COVID-19) has led to significant health burden in infected patients especially in those with underlying comorbidities. The aim of this study was to evaluate the correlation between comorbidities and their role in the exacerbation of disease in COVID-19 patients leading to fatal outcomes. A systematic review was conducted using data from MEDLINE, Scopus, Web of Science, and EMBASE databases published from 1 December 2019 to 15 September 2020. Fifty-three articles were included in the systematic review. Of those 53 articles, 8 articles were eligible for meta-analysis. Hypertension, obesity, and diabetes mellitus were identified to be the most prevalent comorbidities in COVID-19 patients. Our meta-analysis showed that cancer, chronic kidney diseases, diabetes mellitus, and hypertension were independently associated with mortality in COVID-19 patients. Chronic kidney disease was statistically the most prominent comorbidity leading to death. However, despite having high prevalence, obesity was not associated with mortality in COVID-19 patients.
MeSH term(s)	COVID-19/epidemiology ; COVID-19/mortality ; COVID-19/pathology ; Comorbidity ; Hospitalization ; Humans ; Prevalence ; Risk Factors ; SARS-CoV-2 ; Treatment Outcome
Language	English
Publishing date	2021-02-09
Publishing country	United States
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	2557172-2
ISSN	2150-7511 ; 2161-2129
ISSN (online)	2150-7511
ISSN	2161-2129
DOI	10.1128/mBio.03647-20
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Impact of Underlying Comorbidities on Mortality in SARS-COV-2 Infected Cancer Patients: A Systematic Review and Meta-Analysis.

Kaur, Harmanjeet / Thakur, J S / Paika, Ronika / Advani, Shailesh M

Asian Pacific journal of cancer prevention : APJCP

2021 Volume 22, Issue 5, Page(s) 1333–1349

Abstract: ... of comorbidities among cancer patients with SARS CoV-2 infection and their impact on mortality.: Methods: Online ... likely to have severe disease sequel and mortality. In SARS-CoV-2 infected cancer patients risks ... patients.: Results: Total 31studies with 4086 SARS-CoV-2 infectedcancer patientsmet the inclusion ...

Abstract	Background: The evidence has shown that SARS CoV-2 infected patients with comorbidities are more likely to have severe disease sequel and mortality. In SARS-CoV-2 infected cancer patients risks associated with other underlying comorbidities might vary from those in non-cancer SARS CoV-2 infected patients. The relative impact of different underlying health conditions among patients with cancer and SARS CoV-2 infection remains yet to be explored. This systematic review aims to explore the prevalence of comorbidities among cancer patients with SARS CoV-2 infection and their impact on mortality. Methods: Online databases PubMed, Embase, Scopus and Web of science were searched for articles published between 9th July 2019 to July 8th 2020.Studies of cancer patients (>18 years) with diagnosis of SARS CoV-2 infection, published in English were included. A random-effects modelling for the meta-analyses was applied to assess the pooled prevalence and odds ratio for mortality due to comorbidities in SARS CoV-2 infected cancer patients. Results: Total 31studies with 4086 SARS-CoV-2 infectedcancer patientsmet the inclusion criteria. Most prevalent co-morbidities in cancer patients with SARS CoV-2 infection were hypertension [42.3% (95%CI:37.5- 47.0)], diabetes [17.8% (95% CI: 15.3-20.4)] and cardiovascular diseases [16.7% (95%CI:12.9-20.4)].The risk of mortality (pOR) was significantly higher in individuals with hypertension[1.6(95%CI 1.24-2.00)], cardiovascular diseases [2.2 (95%CI 1.49- 3.27)], chronic obstructive pulmonary diseases [1.4(95% CI 1.05-2.00)] and diabetes [1.35(95%CI 1.06-1.73)]. Conclusion: Our results indicates that the mortality in SARS-CoV-2 infected cancer patients is affected by preexisting non-cancer comorbidities. By identifying the comorbidities predictive for mortality, clinicians can better stratify the risk of cancer patients presenting with SARS-COV-2, on their initial contact with health services. .
MeSH term(s)	COVID-19/epidemiology ; COVID-19/mortality ; Comorbidity ; Humans ; Neoplasms/epidemiology ; Neoplasms/mortality ; Neoplasms/therapy
Language	English
Publishing date	2021-05-01
Publishing country	Thailand
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	2218955-5
ISSN	2476-762X ; 1513-7368
ISSN (online)	2476-762X
ISSN	1513-7368
DOI	10.31557/APJCP.2021.22.5.1333
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.

Yang, Jing / Zheng, Ya / Gou, Xi / Pu, Ke / Chen, Zhaofeng / Guo, Qinghong / Ji, Rui / Wang, Haojia / Wang, Yuping / Zhou, Yongning

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

2020 Volume 94, Page(s) 91–95

Abstract: ... in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe ... in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was ... Conclusion: We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying ...

Abstract	Background: An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. Aims: The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients. Methods: A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models. Results: Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86-97%), followed by cough (67.7%, 95% CI: 59-76%), fatigue (51.0%, 95% CI: 34-68%) and dyspnea (30.4%, 95% CI: 21-40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0-27.2%) and diabetes (9.7%, 95% CI: 7.2-12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8-13.8%) and respiratory system disease (1.5%, 95% CI: 0.9-2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46-3.83), 2.46 (95% CI: 1.76-3.44) and 3.42 (95% CI: 1.88-6.22) respectively. Conclusion: We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients.
MeSH term(s)	Betacoronavirus ; COVID-19 ; Comorbidity ; Coronavirus Infections/epidemiology ; Cough ; Fever/etiology ; Humans ; Pandemics ; Pneumonia, Viral/epidemiology ; Prevalence ; Risk Factors ; SARS-CoV-2
Keywords	covid19
Language	English
Publishing date	2020-03-12
Publishing country	Canada
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	1331197-9
ISSN	1878-3511 ; 1201-9712
ISSN (online)	1878-3511
ISSN	1201-9712
DOI	10.1016/j.ijid.2020.03.017
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4516: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Association of Patients' Epidemiological Characteristics and Comorbidities with Severity and Related Mortality Risk of SARS-CoV-2 Infection: Results of an Umbrella Systematic Review and Meta-Analysis.

Reyna-Villasmil, Eduardo / Caponcello, Maria Giulia / Maldonado, Natalia / Olivares, Paula / Caroccia, Natascia / Bonazzetti, Cecilia / Tazza, Beatrice / Carrara, Elena / Giannella, Maddalena / Tacconelli, Evelina / Rodríguez-Baño, Jesús / Palacios-Baena, Zaira R

Biomedicines

2022 Volume 10, Issue 10

Abstract: ... systematic review, including a meta-analysis examining the association between patients’ underlying ... characteristics and comorbidities with SARS-CoV-2 infection severity and related mortality risk. An umbrella ... diagnosed with SARS-CoV-2 infection. Evidence was summarized as pooled odds ratios (pOR) for disease ...

Abstract	The objective of this study was to assess the association between patients’ epidemiological characteristics and comorbidities with SARS-CoV-2 infection severity and related mortality risk. An umbrella systematic review, including a meta-analysis examining the association between patients’ underlying conditions and severity (defined as need for hospitalization) and mortality of COVID-19, was performed. Studies were included if they reported pooled risk estimates of at least three underlying determinants for hospitalization, critical disease (ICU admission, mechanical ventilation), and hospital mortality in patients diagnosed with SARS-CoV-2 infection. Evidence was summarized as pooled odds ratios (pOR) for disease outcomes with 95% confidence intervals (95% CI). Sixteen systematic reviews investigating the possible associations of comorbidities with severity or death from COVID-19 disease were included. Hospitalization was associated with age > 60 years (pOR 3.50; 95% CI 2.97−4.36), smoking habit (pOR 3.50; 95% CI 2.97−4.36), and chronic pulmonary disease (pOR 2.94; 95% CI 2.14−4.04). Chronic pulmonary disease (pOR 2.82; 95% CI 1.92−4.14), cerebrovascular disease (pOR 2.74; 95% CI 1.59−4.74), and cardiovascular disease (pOR 2.44; 95% CI 1.97−3.01) were likely to be associated with increased risk of critical COVID-19. The highest risk of mortality was associated with cardiovascular disease (pOR 3.59; 95% CI 2.83−4.56), cerebrovascular disease (pOR 3.11; 95% CI 2.35−4.11), and chronic renal disease (pOR 3.02; 95% CI 2.61−3.49). In conclusion, this umbrella systematic review provides a comprehensive summary of meta-analyses examining the impact of patients’ characteristics on COVID-19 outcomes. Elderly patients and those cardiovascular, cerebrovascular, and chronic renal disease should be prioritized for pre-exposure and post-exposure prophylaxis and early treatment.
Language	English
Publishing date	2022-09-29
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2720867-9
ISSN	2227-9059
ISSN	2227-9059
DOI	10.3390/biomedicines10102437
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Yang, Jing / Zheng, Ya / Gou, Xi / Pu, Ke / Chen, Zhaofeng / Guo, Qinghong / Ji, Rui / Wang, Haojia / Wang, Yuping / Zhou, Yongning

Int J Infect Dis

Abstract: ... in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe ... in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was ... CONCLUSION: We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying ...

Abstract	BACKGROUND: An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. AIMS: The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients. METHODS: A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models. RESULTS: Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86-97%), followed by cough (67.7%, 95% CI: 59-76%), fatigue (51.0%, 95% CI: 34-68%) and dyspnea (30.4%, 95% CI: 21-40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0-27.2%) and diabetes (9.7%, 95% CI: 7.2-12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8-13.8%) and respiratory system disease (1.5%, 95% CI: 0.9-2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46-3.83), 2.46 (95% CI: 1.76-3.44) and 3.42 (95% CI: 1.88-6.22) respectively. CONCLUSION: We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #8189
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Comorbidities and COVID-19 severity in pediatric patients

Mas Wishnuwardhana Widjanarko / Mutiara Nindya / Glenn Fernandez / Axel Jovito

Paediatrica Indonesiana, Vol 62, Iss 1, Pp 51-

systematic review and meta-analysis

2022 Volume 60

Abstract: ... with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. We used PubMed and ... severity of COVID-19 in pediatric patients. Methods A systematic review was performed in accordance ... 828 pediatric COVID-19 patients, comprising 9,754 patients with comorbidities and 276,074 controls ...

Abstract	Background COVID-19 has spread around the world. Although symptoms in children are often mild, children remain at risk of developing severe or critical forms of COVID-19, especially those with underlying or comorbid medical conditions. Objective To evaluate the association between comorbidities and severity of COVID-19 in pediatric patients. Methods A systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. We used PubMed and Google Scholar to locate observational studies that involved children with RT-PCR-confirmed COVID-19 with comorbidities and compared them with controls without comorbidities. Studies must also involve children with severe COVID-19 and provide the risk of severe COVID-19 in children with and without comorbidities as outcome. We performed a meta-analysis to estimate the pooled odds ratio (OR) of severe COVID-19 in children with vs. without comorbidities. Results We included 41 observational studies with a total of 285,828 pediatric COVID-19 patients, comprising 9,754 patients with comorbidities and 276,074 controls. The comorbidities indentified included obesity, congenital malformations, neurological disease, and genetic syndromes. Children with comorbidities had a significantly higher risk of developing severe COVID-19 compared to those without (pooled OR 4.07; 95%CI 2.31 to 7.19; P<0.00001). Conclusion The presence of comorbidities increases the risk of severe COVID-19 in children.
Keywords	children ; covid-19 ; novel coronavirus ; sars-cov-2 ; Medicine ; R ; Pediatrics ; RJ1-570
Subject code	610
Language	English
Publishing date	2022-02-01T00:00:00Z
Publisher	Indonesian Pediatric Society Publishing House
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.

Naimi, Adel / Yashmi, Ilya / Jebeleh, Reza / Imani Mofrad, Mohammad / Azimian Abhar, Shakiba / Jannesar, Yasaman / Heidary, Mohsen / Pakzad, Reza

Journal of clinical laboratory analysis

2022 Volume 36, Issue 5, Page(s) e24387

Abstract: ... in patients with hematological malignancies.: Material and methods: In this systematic review and ... by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It seems that there is an association between blood cancer and ... SARS-CoV-2, blood cancer, myeloma, lymphoma, and leukemia. All the published articles in English ...

Abstract	Introduction: The global pandemic of coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It seems that there is an association between blood cancer and an increased risk of severe COVID-19. This study aimed to review the literature reporting the COVID-19 outcomes in patients with hematological malignancies. Material and methods: In this systematic review and meta-analysis, Pubmed, Embase, and Web of Science databases were searched using the following keywords: COVID-19, SARS-CoV-2, blood cancer, myeloma, lymphoma, and leukemia. All the published articles in English from January 1, 2019, until March 10, 2021 were collected and evaluated. Results: In total, 53 studies with 2395 patients were included based on inclusion criteria. Most of these studies took place in Spain (14.81%), followed by the USA (11.11%), China (9.26%), and the UK (9.26%). More than half of COVID-19 patients with hematological malignancy were male (56.73%). Oxygen therapy played an important role in COVID-19 treatment. Moreover, anticoagulant therapies such as enoxaparin and heparin were two great assists for these patients. Fever (74.24%), cough (67.64%), and fatigue (53.19%) were the most reported clinical manifestations. In addition, hypertension and dyslipidemia were the most common comorbidities. The mortality rate due to COVID-19 in patients with hematological malignancies was 21.34%. Conclusion: This study demonstrated that hematologic cancer patients were more susceptible to a severe COVID-19 than patients without blood cancer. Thus, the management of COVID-19 in these patients requires much more attention, and their screening should perform regularly.
MeSH term(s)	COVID-19/epidemiology ; Female ; Hematologic Neoplasms/complications ; Hematologic Neoplasms/epidemiology ; Humans ; Male ; Pandemics ; SARS-CoV-2 ; COVID-19 Drug Treatment
Language	English
Publishing date	2022-04-06
Publishing country	United States
Document type	Journal Article ; Meta-Analysis ; Review ; Systematic Review
ZDB-ID	645095-7
ISSN	1098-2825 ; 0887-8013
ISSN (online)	1098-2825
ISSN	0887-8013
DOI	10.1002/jcla.24387
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2471: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comorbidities and autopsy findings of COVID-19 deaths and their association with time to death: a systematic review and meta-analysis.

Martín-Martín, Jaime / Martín-Cazorla, Fernando / Suárez, Juan / Rubio, Leticia / Martín-de-Las-Heras, Stella

Current medical research and opinion

2022 Volume 38, Issue 5, Page(s) 785–792

Abstract: ... a profile of the deceased and the likelihood of time to death.: Methods: A systematic review was carried ... Meta-Analyses and meets Cochrane criteria recommendations (PROSPERO registration number CRD 42020209649 ... Patients with vascular disease, heart disease, and diabetes died significantly in a shorter period of time ...

Abstract	Objective: Examination of postmortem findings can help establish effective therapeutic strategies to reduce mortality. The aim of this study was therefore to review complete autopsy cases and their postmortem findings and comorbidities associated with death caused by COVID-19, in order to establish a profile of the deceased and the likelihood of time to death. Methods: A systematic review was carried out following the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and meets Cochrane criteria recommendations (PROSPERO registration number CRD 42020209649). An electronic search in the databases Pubmed, Scopus, Web of Science, Wiley Online Library, and Scientific Electronic Library Online (SciELO) was performed. Results: The search strategy yielded a total of 25 articles where 140 cases of complete autopsies were reported. The most prevalent comorbidity was vascular diseases. Patients with vascular disease, heart disease, and diabetes died significantly in a shorter period of time. Autopsies mainly focused on the lungs. The proliferative phase of Diffuse Alveolar Damage (DAD) was the most reported in the microscopic postmortem findings, and these patients died in a shorter period of time. However, individuals aged over 80 years significantly presented fibrotic phase of DAD at the time of death. The kidney was the second most affected organ with thrombosis and tubular damage, followed by the liver with congestion and necrosis. Conclusion: Given that accurate information of complete autopsies findings is still scarce, it is necessary to perform complete autopsies by examining organs other than the lungs in order to provide information to improve new treatment strategies in patients with a high risk of mortality.
MeSH term(s)	Aged ; Autopsy ; COVID-19 ; Comorbidity ; Humans ; Lung ; SARS-CoV-2 ; Vascular Diseases
Language	English
Publishing date	2022-03-31
Publishing country	England
Document type	Journal Article ; Meta-Analysis ; Review ; Systematic Review
ZDB-ID	80296-7
ISSN	1473-4877 ; 0300-7995
ISSN (online)	1473-4877
ISSN	0300-7995
DOI	10.1080/03007995.2022.2050110
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 955: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Distinct Symptoms and Underlying Comorbidities with Latitude and Longitude in COVID-19: A Systematic Review and Meta-Analysis.

Tian, Yong / Wu, Qian / Li, Hongwei / Wu, Qi / Xie, Yi / Li, Li / Chen, Huaiyong

Canadian respiratory journal

2022 Volume 2022, Page(s) 6163735

Abstract: ... we performed a systematic review and meta-analysis of clinical features and underlying medical conditions ... significantly higher than those in Asia. Most Asian patients had fever (95%CI 0.70‒0.81), and most Oceanian ... 0.33‒0.64), Europe (95%CI 0.29‒0.64), and high latitude regions (95%CI 0.53‒0.82). European patients ...

Abstract	The coronavirus disease 2019 (COVID-19) pandemic is straining global health resources, and the prevalence of severe disease appears to vary across countries. In accordance with PRISMA guidelines, we performed a systematic review and meta-analysis of clinical features and underlying medical conditions of COVID-19. Eighty-seven studies, involving 1,434,931 COVID-19 patients from the Americas, Asia, Europe, and Oceania, were included. Geographically, the rate of severity was highest in Asia (95% confidence interval (CI) 0.23‒0.30). The rates of comorbidities of COVID-19 patients in the Americas were significantly higher than those in Asia. Most Asian patients had fever (95%CI 0.70‒0.81), and most Oceanian patients had cough (95%CI 0.68‒0.70) as their prevalent symptom. Dyspnea was common in the Americas (95%CI 0.33‒0.64), Europe (95%CI 0.29‒0.64), and high latitude regions (95%CI 0.53‒0.82). European patients exhibited significantly high rates of loss of smell and taste (95%CI 0.60-0.97). In low-latitude regions, cancer (95%CI 14.50‒4.89) had the strongest correlation with illness severity. Comorbid diseases and clinical manifestations of severe COVID-19 patients vary substantially between latitudes and longitudes. Region-specific care should be considered to treat and improve the prognosis of COVID-19 patients.
MeSH term(s)	COVID-19 ; Comorbidity ; Humans ; Pandemics ; Prevalence ; SARS-CoV-2 ; United States
Language	English
Publishing date	2022-01-27
Publishing country	Egypt
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	1213103-9
ISSN	1916-7245 ; 1198-2241
ISSN (online)	1916-7245
ISSN	1198-2241
DOI	10.1155/2022/6163735
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4140: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: COVID-19 and comorbidities: a systematic review and meta-analysis.

Gold, Morgan Spencer / Sehayek, Daniel / Gabrielli, Sofianne / Zhang, Xun / McCusker, Christine / Ben-Shoshan, Moshe

Postgraduate medicine

2020 Volume 132, Issue 8, Page(s) 749–755

Abstract: ... implementation, and resource allocation. We conducted a systematic review and meta-analysis to evaluate ... were included in the systematic review and twenty-two in the meta-analysis. Of the total cases 40.80 ... SARS-CoV-2 has caused a worldwide pandemic that began with an outbreak of pneumonia cases ...

Abstract	SARS-CoV-2 has caused a worldwide pandemic that began with an outbreak of pneumonia cases in the Hubei province of China. Knowledge of those most at risk is integral for treatment, guideline implementation, and resource allocation. We conducted a systematic review and meta-analysis to evaluate comorbidities associated with severe and fatal cases of COVID-19. A search was conducted on PubMed and EmBase on 20 April 2020. Pooled estimates were collected using a random-effects model. Thirty-three studies were included in the systematic review and twenty-two in the meta-analysis. Of the total cases 40.80% (95%CI: 35.49%, 46.11%) had comorbidities, while fatal cases had 74.37% (95%CI: 55.78%, 86.97%). Hypertension was more prevalent in severe [47.65% (95%CI: 35.04%, 60.26%)] and fatal [47.90% (95%CI: 40.33%, 55.48%)] cases compared to total cases [14.34% (95%CI: 6.60%, 28.42%)]. Diabetes was more prevalent among fatal cases [24.89% (95%CI: 18.80%, 32.16%)] compared to total cases [9.65% (95%CI: 6.83%, 13.48%)]. Respiratory diseases had a higher prevalence in fatal cases [10.89% (95%CI: 7.57%, 15.43%)] in comparison to total cases [3.65% (95%CI: 2.16%, 6.1%)]. Studies assessing the mechanisms accounting for the associations between severe cases and hypertension, diabetes, and respiratory diseases are crucial in understanding this new disease, managing patients at risk, and developing policies and guidelines that will reduce future risk of severe COVID-19 disease.
MeSH term(s)	COVID-19/mortality ; COVID-19/prevention & control ; Comorbidity ; Humans ; Noncommunicable Diseases/epidemiology ; Prevalence ; Risk Factors ; Risk Management/methods ; Risk Management/organization & administration ; SARS-CoV-2 ; Severity of Illness Index
Keywords	covid19
Language	English
Publishing date	2020-07-14
Publishing country	England
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	410138-8
ISSN	1941-9260 ; 0032-5481
ISSN (online)	1941-9260
ISSN	0032-5481
DOI	10.1080/00325481.2020.1786964
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.407: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito